




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Chronic GlomerulonephritisDefinitionChronic glomerulonephritis is the advanced stage of a group of kidney disorders, resulting in inflammation and slowly worsening destruction of internal kidney structures called glomeruli. clinical feature: persisting proteinuria、hemoturia、 hypertension 、edema、chro
2、nic renal failure, insidious onset or as a late sequel of acute glomerulonephritis;the kidneys are symmetrically contracted and granular, with scarring and loss of glomeruli and the presence of tubular atrophy and interstitial fibrosis. Etiology and Pathogenesisvaried cause、varied pathology of idiop
3、athic or primary nephritisa few come from AGNHypertension 、proteinuria、hyperlipemia can make CGN progressmay develop after survival of the acute phase of rapidly progressive glomerulonephritis. In about one-quarter of patients with chronic glomerulonephritis, there is no prior history of kidney dise
4、ase, and the disorder first appears as chronic kidney failure.Immune inflammation: major Humoral immunity in situ immune complexe (IC) circulating immune complexe (CIC) Cellular immunity circulating Immune complex depositin situ immune complexe depositPathology Minimal Change Disease (10-15%) Membra
5、nous Glomerulonephritis (25-30%) Focal Segmental Glomerulosclerosis (20-25%) IgA Nephropathy (5-10%) Membranoproliferative Glomerulonephritis (5%)Minimal chang PAS x 410FSGS PAS x 410FSGS PASx260MN。 PAS x 320 MN PASM x 1000 PAS x 260 PAS x 260PASx260 PAS x 100Clinical featureslowing and delitescence
6、proteinuria, hematuria,hypertension,edemaimpairment of renal function acute episode at the end , developed to CRFanergy,fatigue,waist soreness,loss of appetite,edema,et.alBecause symptoms develop gradually, the disorder may be discovered when there is an abnormal urinalysis during a routine physical
7、 or during an examination for another, unrelated disorder. It may be discovered as a cause of high blood pressure that is difficult to control.laboratory examinationurine abnomal:proteinuria,BLD,casts,et.alrenal function insufficiency:increase of BUN,Scr,decrease of Ccr,ripid aggravated for infectio
8、n,tired,blood pressure increase,or nephrotoxicity drugs anemiaTests that may be done include: Chest x-ray Kidney or abdominal CT scan Kidney or abdominal ultrasound IVP Urinalysis A kidney biopsy may show one of the forms of chronic glomerulonephritis or scarring of the glomeruli.Diagnosis abnormal
9、of urine analysis,edema,hypertension,for more than 1 year。except Secondary Nephritis and Hereditary Nephritis。less than 1 year with :acute nephritis sydrome.only midrange proteinuria and light to midrange edema.which need biopsyDifferential diagnosis1.Latent glomerulonephritis:asymptomatic hematuria
10、 and/or proteinuria without edema、hypertension and renal function insufficiency。with lightly pathologic changes。 2. Acute glomerulonephritis 3.Hypertension associated nephropathy 4. Secondary Nephritis(SLE) 5. Hereditary Nephritis:Alport syndrome Treatment Dietary therapy Restriction protein and pho
11、sphorus intakeDietary restrictions on salt, fluids, protein, and other substances may be recommended to help control of high blood pressure or kidney failure. High protein consumption glomerular hyperfiltration, intraglomerular pressure accelerate the progression of nephropathy Restriction protein i
12、ntake blunt urinary albumin excretiondecline GFRDietary therapyDietary therapyDietary Protein RestrictionReduce protein intake to 1g/d, target BP is 125/75mmHg.If proteinuria 1g/d, target BP is 130/80mmHg.Correction of Anemia use EPO, add Ferrum and folate acidAnemia enhances renal hypoxia, which st
13、imulates release of profibrotic cytokinesErythropoietin therapy and correction of anemia may slow CKD progressionTarget Hb 12 g/dLTreatment of Dyslipidemiaslow fat diet,exercise, medicineDyslipidemia is common in CKD (VLDL; LDL; HDL)Evidence that dyslipdemias may initiate CKD and accelerate progress
14、ion of CKDMechanism unclearStatins CKD progressionStatins also risk of atherosclerotic CVD, which is main cause of mortality in CKD patientsTarget LDL 100 mg/dLTight glycemic control in diabetics (HbA1c 6.5%)Dietary salt restriction ( 5 g/d)Weight control (BMI 25)Antiplatelet therapyAvoid nephrotoxic drugschinese herbs(rhubarb)Other StrategiesCorticosteroids and immunosuppressives according to pathologic type,proteinuria,renal functionPrognosisThe outcome varies depending on the cause. Some types of glomerulonephritis may get better on their own.At the end,CGN will progress to uremiaThere
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 創(chuàng)業(yè)直播帶貨計劃書模板
- 中建2022工作報告
- 合同三方協(xié)議書范本
- 中國半胱胺鹽酸鹽項(xiàng)目創(chuàng)業(yè)計劃書
- 轉(zhuǎn)租協(xié)議書三方合同
- 環(huán)保農(nóng)場創(chuàng)業(yè)計劃書范文
- 中國商用采暖空氣源熱泵行業(yè)市場占有率及投資前景預(yù)測分析報告
- 餐飲員工合同協(xié)議書范本
- 2025年主治醫(yī)生述職報告模版(三)
- 企業(yè)數(shù)字化轉(zhuǎn)型路線圖與關(guān)鍵策略點(diǎn)
- 續(xù)簽采購合同范本(標(biāo)準(zhǔn)版)
- 智能垃圾分類箱項(xiàng)目投資商業(yè)計劃書范本(投資融資分析)
- 2025至2030中國胸腺法新行業(yè)深度調(diào)查及投資前景研究報告
- 國有企業(yè)合同管理辦法3篇
- 廣西南寧市2025屆普通高中畢業(yè)班第二次適應(yīng)性考試(二模)數(shù)學(xué)試題【含答案】
- 2025-2030中國調(diào)光玻璃行業(yè)規(guī)模走勢及投資可行性分析研究報告
- 《明朝的邊疆政策》課件
- 湖北省武漢市2025屆高中畢業(yè)生四月調(diào)研考試生物試題及答案(武漢四調(diào))
- 2025年山東濟(jì)南歷城金融控股集團(tuán)有限公司招聘筆試參考題庫含答案解析
- 技術(shù)合作協(xié)議范本
- 2025年度建筑施工安全演練計劃
評論
0/150
提交評論